So overall, this paper makes the prospects for a vaccine look good: there is indeed a robust response by the adaptive immune system, to several coronavirus proteins. And vaccine developers will want to think about adding in some of the other antigens mentioned in this paper, in addition to the Spike antigens that have been the focus thus far. It seems fair to say, though, that the first wave of vaccines will likely be Spike-o-centric, and later vaccines might have these other antigens included in the mix. But it also seems that Spike-protein-targeted vaccines should be pretty effective, so that’s good. The other good news is that this team looked for the signs of an antibody-dependent-enhancement response, which would be bad news, and did not find evidence of it in the recovering patients (I didn’t go into these details, but wanted to mention that finding, which is quite reassuring). And it also looks like the prospects for (reasonably) lasting immunity after infection (or after vaccination) are good. This, from what I can see, is just the sort of response that you’d want to see for that to be the case. Clinical data will be the real decider on that, but there’s no reason so far to think that a person won’t have such immunity if they fit this profile.
Onward from here, then – there will be more studies like this coming, but this is a good, solid look into the human immunology of this outbreak. And so far, so good.
Be sure to read the article if you’ve been wondering what your thymus has done for you lately.